Panels

10:30

Healthcare at Home

Revolutionizing the future of patient management through the adoption of home healthcare products.

Overseeing telemedicine technology operations, technology research and development, and finance, Mr. McClure is responsible for managing ongoing research programs at the Center for Connected Health. These R&D programs are focused on helping reduce the barriers between patients and clinicians through the use of simple, accessible technologies, such as the Internet, cell phones and digital cameras.

Mr. McClure is currently the Chair of the American Telemedicine Association Technology Special Interest Group, and is a frequent lecturer on connected health and telemedicine. He is also a member of the Healthcare Information and Management Systems Society, the Massachusetts Technology Council and the Project Management Institute.

Dr. Lustgarten was born and raised in a suburb of New York City. He graduated Magna Cum Laude from Brown University with a Bachelors degree in Biochemistry. He obtained his MD and PhD degrees at the Albert Einstein College of Medicine in the Bronx. Dr. Lustgarten did his medical residency, general cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital in Boston. Subsequently he spent 2 years on faculty at the University of Oklahoma working with Dr. Warren "Sonny" Jackman, Director of an internationally renowned center for radiofrequency ablation management of complex arrhythmias. Currently he works with Drs Peter Spector, Mark Capeless and Robert Lobel at The University of Vermont College of Medicine/Fletcher Allen Health Care Hospital. His clinical focus includes implantation and management of biventricular pacing and the performance of radiofrequency ablation procedures in the management of complex arrhythmias. His research interests include the role of autonomic innervation in atrial fibrillation pathogenesis, the development and improvement of new ablation and mapping technologies and techniques, device management of congestive heart failure, and the role of non-surgical epicardial mapping and ablation in clinical electrophysiology. He is the principal investigator at UVM on several multicenter device protocols.

Dr. Lustgarten is a member of the Phi Beta Kappa and Alpha Omega Alpha Honors Societies, as well as the Sigma Xi Scientific Research Society.

Darrell Johnson joined Medtronic in June 2007. As Vice President of Patient Management, he is responsible for the global business strategy, deployment and utilization of technologies that will increase implanted cardiac device follow-up efficiency. This includes the Medtronic CareLink® Network for data capture within the patient’s home, instruments including programmers, home monitors, and other device readers and connectivity solutions that digitally distribute implanted device data for electronic viewing and storage.

During the past several years, Johnson has built an expertise in working within the medical device industry, identifying how wireless technologies may be applied to improve patient outcomes, decrease utilization costs, and increase care provider efficiency. His passion centers on not simply bringing wireless technologies to market, but the successful implementation and utilization of these technologies.

Prior to joining Medtronic, Johnson held several positions at GE Healthcare, including U.S. Marketing Manager for GE Healthcare X-Ray, General Manager, Telemetry and Networking for GE Healthcare, Global Marketing Manager, Telemetry for GE Healthcare, Global Marketing Manager, Portable Monitoring at GE Healthcare.

He also served as General Manager of Porous Media Corporation, Marketing Manager at Porous Media Corporation, Commercial Lending Officer and Commercial Lending Analyst, American National Bank.

Johnson holds a bachelor of science degree in mathematics and economics from the University of Minnesota and an MBA from the Carlson School of Management, University of Minnesota.

Gary Inglese, R.N., M.B.A. has spent over 30 years in the healthcare industry in various capacities. He worked as a nurse in an emergency room setting prior to joining Indiana Medical Associates, LLC, a 32 physician multi-specialty internal medicine practice as the Chief Operations Officer. In March 2004, he joined International Nephrology Network, a division of International Physician Networks, an AmerisourceBergen Specialty Group Company, as the National Director of Sales and Marketing. Duties included responsibility for the strategic business and marketing initiatives of a highly integrated nephrology physician services organization. While there, he developed a comprehensive program providing consultative services to nephrology practices on optimizing resources to enhance patient care. In 2006, he joined Baxter Healthcare Corporation, Chicago, where he currently serves as the Director, U.S. Health Economics and Reimbursement for the Renal division. He is accountable for developing and executing the health economic and reimbursement strategies.

Derek joined Baxter in 2007 and is responsible for running the hemodialysis business unit support team in the R&D group. Duties include supporting the 35,000+ hemodialysis devices Baxter has placed around the world as well as working with global partners to source the latest generation of disposables and hardware for the in-center hemodialysis business. Prior to Baxter, Derek worked at Aksys Ltd for 11 years where he developed pioneering devices for the home hemodialysis marketplace. Aksys was an innovator in bringing the hemodialysis treatment back to the home environment by automating many of the operator's actions in an extremely safe and easy to use device. Derek has a biomedical engineering degree from Boston University and is working on his MBA at Northwestern University's Kellogg School of Management.

Panel Lead

Heather Pichette, MBA 2009

Clayton Poppe, MBA 2009

Social Entrepreneurship

An in-depth look at for-profit vs. non-profit models.

Dr. Anita Goel, MD, PhD founded Nanobiosym, Inc in 2004 as an R&D engine that focuses on emerging technologies at the convergence of Physics, Medicine, and Nanotechnology. Dr. Goel’s pioneering contributions to this interface over the past 15 years have been recognized globally by several prestigious honors and awards. A Harvard-MIT trained physicist and physician, Dr. Goel was named in 2005 as one of the world’s “Top 35 science and technology innovators under the age of 35” by MIT’s Technology Review Magazine and in 2006 received the Global Indus Technovator Award from MIT, an honor recognizing the contributions of top 10 leaders working at the forefront of science, technology, and entrepreneurship. Dr. Goel holds both a PhD in Physics from Harvard University and an MD from the Harvard-MIT Joint Division of Health Sciences and Technology (HST) and BS in Physics with Honors & Distinction from Stanford University. She is a Fellow of the World Technology Network, a Fellow-at-Large of the Santa Fe Institute, and an Associate of the Harvard Physics Department and Adjunct Professor of the BEYOND Institute for Fundamental Concepts in Science.

Eugene Hill joined SVLS in 1999. He was previously a Partner at Accel Partners in Palo Alto, California for five years, where he was responsible for 13 investments in early stage healthcare service and healthcare information technology companies. He is currently on the Board of Synarc, Cadent, Patient Care, Medifacts, Socios Mayores en Salud, US Renal Care and Accelecare Wound Centers.

Prior to joining Accel Partners, Eugene held several senior management positions, most recently, President of Behavioral Health at United HealthCare Corporation, CEO and President of US Behavioral Health and President and Chairman of Sierra Health and Life Insurance Company.

Eugene has 19 years of operating experience in the US healthcare services market. Eugene has a BA from Middlebury College and an MBA from Boston University.

Vikram Sheel Kumar is a pioneer in the field of community based chronic disease management. He received a bachelor of science degree with honors in operations research from Columbia University. During his time at Columbia, he invented and patented a software tool to analyze multidimensional neuronal data.

The son of an inventive neurosurgeon Dr. Vijay Sheel Kumar, Vikram invented a privatizing fax machine with his father at the age of 14. In 1999, Vikram joined the MIT Media Laboratory as a research assistant and with his advisor Sandy Pentland invented DiaBetNetTM that was nominated as one of the top ten designs of the decade by BusinessWorld magazine.

While in the M.D. program at the Harvard-MIT Division of Health Sciences and Technology, Vikram met Vishwananth Anantraman and Tarjei Mikkelsen and together started Dimagi in 2002. Vikram concurrently completed his medical degree and began a residency in Clinical Pathology at the Brigham and Women's Hopsital.

In 2004, Vikram was named the MIT Technology Review's Humanitarian of the Year and one of the world's 100 top innovators. He is a Paul and Daisy Soros New American, a founding Fellow of Media Lab Asia, a member of the advisory board of the Global Emerging Technology Institute and a board director of the Bienmoyo Foundation.

Peter T. Lomedico, Ph.D. joined the Juvenile Diabetes Research Foundation (JDRF) in August 2005 to lead the foundation’s industry partnership program. Dr. Lomedico has a diverse background in molecular biology, diabetes research and drug discovery, with over 25+ years of pharmaceutical and biotechnology experience. Previously he worked at NeoGenesis Corporation as Vice President, Strategic Alliances, CuraGen Corporation as Vice President, Discovery Research and Genome Therapeutics Corporation as Vice President, Human Genetics. Dr. Lomedico conducted genomics and drug discovery research in various positions at Hoffmann-LaRoche, Inc. Dr. Lomedico received his B.S. from Villanova University, his Ph.D. from the University of Texas at Houston, and was a JDRF postdoctoral research fellow in the laboratory of Prof. W. Gilbert at Harvard University.

Panel Leads

Debbie Schapira, MBA 2009

Steve Yerid, MBA 2009

2:00

R&D - Is Innovation Dead?

What factors are determining the roadmap in R&D today?

Charles Cooney is a Professor of Chemical Engineering, in the Department of Chemical Engineering , the Faculty Director of the Deshpande Center for Technological Innovation, and the International Innovation Initiative (I3) at MIT. He received the 1989 Gold Medal of the Institute of Biotechnological Studies (London), the Food, Pharmaceutical and Bioengineering Award from the American Institute of Chemical Engineers and the James Van Lanen Distinguished Service Award from the American Chemical Society's Division of Microbial and Biochemical Technology and was elected to the American Institute of Medical and Biochemical Engineers. He serves as a consultant to a number of biotech and pharmaceutical companies, is on several editorial boards of professional journals, sits on the Boards of Directors of Genzyme, BioProcessors, LS9, Inc. and Biocon, Ltd (India), He chaired the FDA Advisory Committee for Pharmaceutical Science from 2004-2006. His research interest include manufacturing strategy in the pharmaceutical, biotech and biofuels industries, as well as bioprocess design, operation and control, and processing of pharmaceutical powders. His teaching has focused on bioprocessing, drug development and technological innovation.

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut. Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley. Mr. Fleming is a co-founder and Chairman of the Board of Memory Pharmaceuticals (NASDAQ: MEMY). He is also Chairman of the Board of BioProcessors Corporation and is a director of several private companies including Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer at the MIT Sloan School of Business.

Douglas is a Professor in the Department of Mechanical Engineering at MIT and an inventor, co-founder, interim CTO, and former board member of Brontes Technologies, Inc., a MIT Deshpande Center spinout acquired by 3M in 2006. Douglas has a long history of successful commercial inventions from within and outside academia. He is an advisor for numerous companies and professional organizations and he has received a number of awards for his research and teaching.

Dr. Brennan is currently Director of Strategic Alliances at Novartis Institutes of BioMedical Research, Inc. In this role she leads all the business development activities of the infectious disease research group. She is responsible for in-licensing technologies and compounds to support the strategic objectives of this group. Prior to Novartis, Dr. Brennan was Director of Business Development at the biotechnology company EnVivo Pharmaceuticals as well as Director at Fidelity Biosciences Group, the primary investor of EnVivo. Prior to EnVivo, Dr. Brennan held senior positions in business development and strategic planning in Biovail Pharmaceuticals, a mid-size pharmaceutical company as well as the biotechnology company Cogent Neurosciences, Inc. Prior to Cogent, Dr. Brennan was a Manager at the healthcare consulting firm, Kendall Strategies. Dr. Brennan received her PhD. in 1995 in neurophysiology from Dartmouth Medical School

Jonathan is an experienced life science entrepreneur with a strong executive management and business development track record. Jonathan founded Extera Partners, where he leads investment activities as well as partnering, financing, M&A, and corporate strategy efforts for private and public life science companies. Prior to Extera, Jonathan also founded Cardio Response, Protein Forest, and Gelesis. He was Vice President with Coordinated Care Solutions; and earlier in his career led IBM's healthcare business in Israel. Jonathan practiced emergency medicine and has published in leading medical journals. He earned his MD from the Technion Institute of Technology in Israel and his MBA from the Harvard Business School.

Panel Lead

Eric Cheung, MBA 2008

The First $10 Million - Going From Bench to Bedside

Exploring the pathways and pitfalls to commercialization.

Michael is a General Partner at Flybridge Capital Partners focused on information technology, healthcare and medical technology investments. Among a range of general investment themes, Michael is currently focused on opportunities involving, the convergence of healthcare and IT, technology-enabled business services, and technologies that address the physical security and homeland defense markets. Michael currently represents the firm on the boards of BlueTarp, MicroCHIPS, Predictive Biosciences, Protein Forest and VidSys and led the firm’s investment in T2 Biosystems and Magen BioSciences.

Michael founded IDG Ventures Atlantic in 2001 before it transitioned to Flybridge Capital Partners in 2008. Michael continues to serve on the board of International Data Group, the flagship Limited Partner for the IDG Ventures global network of funds.Previously, Michael was with Polaris Venture Partners, where he focused on both early-stage and later-stage financings for emerging growth companies. Before Polaris, Michael served as Senior Vice President and Founding Partner of GCC Investments, a $200 million private equity fund. Prior to GCC Investments, Michael was a Vice President and one of the early professionals at Wasserstein Perella & Co., an international merchant bank with a $1.0 billion private equity fund. Additionally, Michael was a member of the Mergers and Acquisitions Department of Morgan Stanley & Co. and worked in the Leveraged Buyout Group of Credit Suisse First Boston.

Michael currently serves as the President of the New England Venture Capital Association and serves on the investment committee of the Partners Healthcare Fund. He is also a member of the Executive Business Advisory Council for Mass General Hospital for Children, and a trustee and on the investment committee of the Massachusetts Eye and Ear Infirmary. Additionally Michael authors a column called “Nothing Ventured” for BioIT World magazine and is an xconomist for Xconomy. Michael received a BA with honors in Chemistry from Williams College and an MBA from Harvard Business School.

Janet Wolfe is President and Founder of Wolfe Laboratories (WLI), a contract research and development group located in Watertown, Massachusetts. WLI provides pharmaceutical R&D in the areas of formulation and bioanalytical support, leveraging its development expertise to help advance early stage compounds into the clinic.

Prior to starting Wolfe Laboratories, Dr. Wolfe was on the faculty of the department of Pharmaceutical Sciences at the University of Tennessee, Memphis. Dr. Wolfe has over fifteen years experience in pharmaceutical research and development and is the author of numerous articles and presentations. She received her BS from University of Sciences in Philadelphia and doctorate in pharmaceutical chemistry from the University of Kansas.

Upon completing his doctorate in Physiology in 1980, Dr. Dasse carried out research in neuromuscular and cardiovascular disorders at Boston University School of Medicine and Tufts University Medical School until 1985. He joined Thermedics Inc. in 1985 where he headed up product development in the areas of chronic percutaneous access, peritoneal dialysis, and vascular access. He was one of the original officers of Thermo Cardiosystems Inc, formed in 1988, where he played a key role in commercializing the first implantable ventricular assist system for end stage heart failure patients until 1996.

Dr. Dasse subsequently joined the Thermo Biomedical Group of Thermo Electron Corporation where he served as Vice President with a focus on the Respiratory, Neurodiagnostic, Cardiovascular and Imaging markets. Dr. Dasse currently serves as President and CEO of Levitronix LLC, as well as COO of Pharos LLC. He served as a Core Technology Advisory Board Member for Battelle Memorial Institute. He previously served as director of Given Imaging located in Israel, and is currently a director of Levitronix LLC, Afferent Corporation, Endovalve Corporation and Geno LLC. Dr. Dasse received his Doctorate in Physiology from Boston University. He has written over 75 journal articles, multiple book chapters and has five patents.

Nicholas G. “Nicho” Hatsopoulos, Ph.D. is currently an Associate Professor at the University of Chicago. Dr. Hatsopoulos is a member of the Department of Organismal Biology and Anatomy as well as the Committees on Computational Neuroscience and Neurobiology. He is currently running a laboratory with five graduate students, two postdoctoral fellows, and several technicians which is funded in part by the National Institutes of Health. From January 1998 to December 2001, Dr. Hatsopoulos was an Assistant Professor of Research in the Department of Neuroscience at Brown University. Dr. Hatsopoulos completed two postdoctoral research fellowships, one in the Department of Neuroscience at Brown University and the other in the Computational Neuroscience Program at the California Institute of Technology. Dr. Hatsopoulos completed his B.A. in Physics from Williams College in 1984, his M.S. in Psychology in 1991 and his Ph.D. in Cognitive Science from Brown University in 1992.

In 2001, he co-founded a company, Cyberkinetics Neurotechnology Systems, which is taking the basic scientific research he and his colleagues have conducted to develop neural prosthesis technology to assist people with severe motor disabilities. He is currently a Board Director and a consultant to the company. His research focuses on the neural basis of motor control and learning. He is investigating what features of motor behavior are encoded and how this information is represented in the collective activity of neuronal ensembles in the motor cortex. He is also interested in how these representations change as motor learning occurs. To answer these questions, the electrical discharge of many motor cortical neurons is simultaneously recorded using multi-electrode arrays and correlated with motor behavior. The encoding properties of individual motor cortical neurons are being studied to determine how these single cell properties relate to higher-order representations involving groups of neurons. The possibility that changes in functional connectivity among neurons may occur during motor learning is also being explored. Dr. Hatsopoulos has authored over 30 peer-reviewed articles, reviews, and book chapters and has given over 70 invited lectures and scientific presentations. He is fluent in Greek, enjoys cooking, and plays tennis and the bouzouki, a Greek folk musical instrument.

Before founding Xconomy, a news site and events company specializing in "hyper-local" information about innovation and the exponential economy, Bob was a research fellow in MIT's Center for International Studies. He previously served as Editor in Chief of MIT's Technology Review magazine and was BusinessWeek's technology editor, where he shared in the 1992 National Magazine Award for "The Quality Imperative." Bob is also the author of three books about technology and innovation, the most recent being Guanxi (Simon and Schuster 2006), which looks at Microsoft's Beijing research lab as a metaphor for global competitiveness. Bob served on the Council on Competitiveness–sponsored National Innovation Initiative and is an advisor to the Draper Prize Nominating Committee. He has been a regular guest of CNBC's Strategy Session and has spoken about innovation to many organizations, including the Business Council, Amazon, eBay, Google, IBM, and Microsoft.

Panel Lead

Charity Akpala, MBA 2009

Andrew Koert, MBA 2009

3:30

Is the World Ready for MyGenomeOnTheWeb.com?

The implications of cheap, fast genomic data

Jorge Conde is President and CEO of Knome, Inc. He has spent his entire professional career in the biotechnology industry, working in finance, business development, marketing and operations. Prior to Knome, Mr. Conde worked in strategic marketing and operations at MedImmune, Inc. He has also worked in business development at Helicos Biosciences Corporation, a DNA sequencing company, and in the life sciences group at Flagship Ventures, a venture capital firm. Previously, Mr. Conde was an investment banker at Morgan Stanley & Co., specializing in the biotechnology and genomics industries. He holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology (HST) and a Bachelor's degree in Biology from The Johns Hopkins University.

Noubar is a technologist, entrepreneur and venture capitalist. He has founded and helped build 15 successful life science and technology startups during the past two decades. In addition, he is a Senior Lecturer at MIT in both the Sloan School of Management and the Biological Engineering Department. Noubar has authored numerous scientific publications as well as patents, and earned his Ph.D. in Biochemical Engineering from MIT in 1987.

In 1999 Noubar co-founded Flagship Ventures, an early stage venture capital and entrepreneurship firm. Prior to that, he participated in creating and launching six highly successful new ventures. He was the Founder, Chairman, and CEO of PerSeptive Biosystems (NASDAQ: PBIO), a leader in the bio-instrumentation field. He also served as Chairman of the Board of ChemGenics Pharmaceuticals, a pioneer in genomics-based drug discovery that was a spin-off company of PerSeptive. After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of their tracking stock subsidiary, Celera Genomics (NYSE: CRA). He has also been a founding team member, investor and active board member/advisor of Antigenics (NASDAQ: AGEN), Color Kinetics (NASDAQ: CLRK) and EXACT Sciences (NASDAQ: EXAS).

Noubar currently serves as a Director for the following Flagship portfolio companies in which he is part of the founding team: Adnexus Therapeutics, Affinnova, BG Medicine, Codon Devices, Ensemble Discovery, Genstruct, Helicos BioSciences (NASDAQ:HLCS), T2 Biosystems and LS9. He is also engaged as an advisor with Flagship portfolio companies BIND Biosciences, Epitome Biosystems, and Mascoma. In addition, he is a member of the Boston University Board of Overseers and a member of several advisory boards including the Whitehead Institute at MIT, the Harvard-MIT Division of Health Sciences and Technology (HST), the Boston University Medical School and the Skolkovo School of Management in Moscow. He is also a founder/board member of Armenia 2020, an international economic development project focusing on the former Soviet Republic of Armenia.

Mark Boguski joined the Novartis Institutes for BioMedical Research (NIBR) in January 2005, both to found and to grow NIBR’s new integrated program in Genome and Proteome Sciences. In this position, he will oversee the critical interface of current genomic services (IK@N and Functional Genomics) with all Disease Areas and Platforms, as well as develop additional expertise necessary for the ongoing success of all NIBR research units.

Mark is well-known globally for his leadership and expertise in bioinformatics. Most recently he has served as the Director of the Allen Brain Atlas project, in addition to holding affiliate faculty appointments at the Fred Hutchinson Cancer Research Center and in the Department of Medicine/Genetics at the University of Washington. Prior to that, Mark was the senior vice president of Research and Development for Rosetta Inpharmatics, Inc. from 2000-2001.

Between 1989 and 2000, Mark was involved with the development of a number of high-impact, enabling information resources at the National Center for Biotechnology Information (NCBI). These include: dbEST; applications of UniGene for creation of the first large-scale maps of the human genome and the design of gene chips from expression profiling; and ArrayDB for management and analysis of expression data. He has also made significant research contributions to comparative genomics and pharmacogenomics.

Mark Boguski is the author or co-author of more than 100 scholarly books and articles and is the recipient of the Regents’ Award from the National Library of Medicine and the Director’s Award from the National Institutes of Health. He is a former editor of Genome Research, has served on the board of reviewing editors for Science magazine and is currently editor-in-chief of Genomics. He has been an organizer of the Cold Spring Harbor Symposium on DNA Mapping, Sequencing & Biology, a member of the scientific advisory board of the Merck Genome Research Institute, a member of the Genetics Advisory Group for the Wellcome Trust and an advisor to the Howard Hughes Medical Institute. In 2001 Mark was honored with election to the Institute of Medicine of the U.S. National Academy of Sciences and also as a fellow of the American College of Medical Informatics.

Mark received his M.D. and Ph.D. degrees from the Medical Scientist Training Program at the Washington University School of Medicine in St. Louis and pursued specialty training in pathology.

Ronald Ranauro is President and CEO of GenomeQuest Inc., a venture-backed genomic information company providing applications and services to manage and mine the world's sequence data. Ranauro participated in the growth and maturity of the Electronics Computer Aided Engineering (ECAE) industry from the early 1980's to the late 1990's. There he honed the basic selling, marketing and business strategies that have helped GenomeQuest attract $8 million in funding and navigate its technology and business model from the post-Internet bust in 2002 to its current position in 2008 with more than 140 customers. Before joining GenomeQuest he founded and led Blackstone Technology Group, a grid-computing provider to the life science IT field. Ron serves as an Entrepreneur-In-Residence at the Clark University Innovation and Entrepreneurship program where he teaches a class in Entrepreneurial Communication and Influence. Also, Ron serves on the Executive Council of the Worcester Polytechnic Institute Department of Management. He earned a BS degree in management engineering in 1983 and an MS in computer science in 1988, both from Worcester Polytechnic Institute.

Steven Dickman, CEO of CBT Advisors, is a biotechnology industry consultant in Cambridge. CBT Advisors’ activities include corporate positioning and strategy; communications and fund-raising materials; and market analysis based on research and expert interviews. Clients include private and public biotech companies and life science venture funds.Before founding CBT Advisors in 2003, Mr. Dickman spent four years in venture capital with TVM Capital. There, Mr. Dickman’s deals included Sirna Therapeutics, sold to Merck in 2006 for $1.1 billion. Earlier, he was a Knight Science Journalism Fellow at MIT, a freelance contributor to The Economist, Discover and Science, and the founding bureau chief for Nature in Munich, Germany. Mr. Dickman got his biochemistry degree cum laude from Princeton University.

Panel LeadS

Kristi Skorija, MBA 2009

Atul Gupta, MBA 2009